Status:
UNKNOWN
REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study
Lead Sponsor:
Immune Response BioPharma, Inc.
Conditions:
HIV/AIDS
Eligibility:
All Genders
3-16 years
Phase:
PHASE2
Brief Summary
The primary objective is to compare \& evaluate between the treatment groups the changes in decline/reduction of HIV viral load \& increase changes in WBC white blood cell counts in the adult Remune d...
Detailed Description
This is a 26 subject Multi Center double-blind randomized, Safety \& Efficacy, pediatric HIV/AIDS Phase II study, to primarily to evaluate the safety and efficacy of HIV-1 immunogen and secondarily to...
Eligibility Criteria
Inclusion
- Children clinically diagnosed with HIV that are 3 months of age to the age 16 years old
- Subjects on any approved FDA antiviral medication except triple cocktail HAART drugs
Exclusion
- Truvada
- Triple cocktail HAART drugs
- Healthy subjects
Key Trial Info
Start Date :
November 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2019
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT02291809
Start Date
November 1 2017
End Date
November 1 2019
Last Update
February 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Site TBA
San Diego, California, United States, 92101